Cyclooxygenase product inhibition with acetylsalicylic acid slows disease progression in the Han:SPRD-Cy rat model of polycystic kidney disease

Naser H.M. Ibrahim, Melanie Gregoire, Jessay G. Devassy, Yinhong Wu, Daisuke Yoshihara, Tamio Yamaguchi, Shizuko Nagao, Harold M. Aukema

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Renal cyclooxygenase (COX) derived eicosanoids are elevated and lipoxygenase (LOX) products are reduced in the Han:SPRD-Cy rat model of polycystic kidney disease (PKD). Selective COX2 inhibition reduces kidney disease progression, but COX1 levels also are elevated in this model. Since the effect of reducing the products of both COX isoforms and the role of LOX products is not known, weanling normal and diseased Han:SPRD-cy littermates were given either low dose acetylsalicylic acid (ASA), nordihydroguaiaretic (NDGA) or no treatment for eight weeks. Renal eicosanoids were altered in the diseased compared to normal cortex, with COX products being higher and LOX products being lower. ASA reduced COX products, cyst growth and kidney water content, while NDGA reduced LOX products without altering disease progression or kidney function. Hence, a human equivalent ASA dose equal to less than one regular strength aspirin per day slowed disease progression, while further reduction of LOX products did not worsen disease progression.

Original languageEnglish
Pages (from-to)19-25
Number of pages7
JournalProstaglandins and Other Lipid Mediators
Volume116-117
DOIs
Publication statusPublished - 01-01-2015

Fingerprint

Polycystic Kidney Diseases
Lipoxygenase
Prostaglandin-Endoperoxide Synthases
Aspirin
Disease Progression
Rats
Kidney
Eicosanoids
Kidney Diseases
Water content
Cysts
Protein Isoforms
Water
Growth

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Physiology
  • Pharmacology
  • Cell Biology

Cite this

Ibrahim, Naser H.M. ; Gregoire, Melanie ; Devassy, Jessay G. ; Wu, Yinhong ; Yoshihara, Daisuke ; Yamaguchi, Tamio ; Nagao, Shizuko ; Aukema, Harold M. / Cyclooxygenase product inhibition with acetylsalicylic acid slows disease progression in the Han:SPRD-Cy rat model of polycystic kidney disease. In: Prostaglandins and Other Lipid Mediators. 2015 ; Vol. 116-117. pp. 19-25.
@article{55fe7180a5584f04a3ba7b661df3d15c,
title = "Cyclooxygenase product inhibition with acetylsalicylic acid slows disease progression in the Han:SPRD-Cy rat model of polycystic kidney disease",
abstract = "Renal cyclooxygenase (COX) derived eicosanoids are elevated and lipoxygenase (LOX) products are reduced in the Han:SPRD-Cy rat model of polycystic kidney disease (PKD). Selective COX2 inhibition reduces kidney disease progression, but COX1 levels also are elevated in this model. Since the effect of reducing the products of both COX isoforms and the role of LOX products is not known, weanling normal and diseased Han:SPRD-cy littermates were given either low dose acetylsalicylic acid (ASA), nordihydroguaiaretic (NDGA) or no treatment for eight weeks. Renal eicosanoids were altered in the diseased compared to normal cortex, with COX products being higher and LOX products being lower. ASA reduced COX products, cyst growth and kidney water content, while NDGA reduced LOX products without altering disease progression or kidney function. Hence, a human equivalent ASA dose equal to less than one regular strength aspirin per day slowed disease progression, while further reduction of LOX products did not worsen disease progression.",
author = "Ibrahim, {Naser H.M.} and Melanie Gregoire and Devassy, {Jessay G.} and Yinhong Wu and Daisuke Yoshihara and Tamio Yamaguchi and Shizuko Nagao and Aukema, {Harold M.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.prostaglandins.2014.10.005",
language = "English",
volume = "116-117",
pages = "19--25",
journal = "Prostaglandins and Other Lipid Mediators",
issn = "1098-8823",
publisher = "Elsevier Inc.",

}

Cyclooxygenase product inhibition with acetylsalicylic acid slows disease progression in the Han:SPRD-Cy rat model of polycystic kidney disease. / Ibrahim, Naser H.M.; Gregoire, Melanie; Devassy, Jessay G.; Wu, Yinhong; Yoshihara, Daisuke; Yamaguchi, Tamio; Nagao, Shizuko; Aukema, Harold M.

In: Prostaglandins and Other Lipid Mediators, Vol. 116-117, 01.01.2015, p. 19-25.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cyclooxygenase product inhibition with acetylsalicylic acid slows disease progression in the Han:SPRD-Cy rat model of polycystic kidney disease

AU - Ibrahim, Naser H.M.

AU - Gregoire, Melanie

AU - Devassy, Jessay G.

AU - Wu, Yinhong

AU - Yoshihara, Daisuke

AU - Yamaguchi, Tamio

AU - Nagao, Shizuko

AU - Aukema, Harold M.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Renal cyclooxygenase (COX) derived eicosanoids are elevated and lipoxygenase (LOX) products are reduced in the Han:SPRD-Cy rat model of polycystic kidney disease (PKD). Selective COX2 inhibition reduces kidney disease progression, but COX1 levels also are elevated in this model. Since the effect of reducing the products of both COX isoforms and the role of LOX products is not known, weanling normal and diseased Han:SPRD-cy littermates were given either low dose acetylsalicylic acid (ASA), nordihydroguaiaretic (NDGA) or no treatment for eight weeks. Renal eicosanoids were altered in the diseased compared to normal cortex, with COX products being higher and LOX products being lower. ASA reduced COX products, cyst growth and kidney water content, while NDGA reduced LOX products without altering disease progression or kidney function. Hence, a human equivalent ASA dose equal to less than one regular strength aspirin per day slowed disease progression, while further reduction of LOX products did not worsen disease progression.

AB - Renal cyclooxygenase (COX) derived eicosanoids are elevated and lipoxygenase (LOX) products are reduced in the Han:SPRD-Cy rat model of polycystic kidney disease (PKD). Selective COX2 inhibition reduces kidney disease progression, but COX1 levels also are elevated in this model. Since the effect of reducing the products of both COX isoforms and the role of LOX products is not known, weanling normal and diseased Han:SPRD-cy littermates were given either low dose acetylsalicylic acid (ASA), nordihydroguaiaretic (NDGA) or no treatment for eight weeks. Renal eicosanoids were altered in the diseased compared to normal cortex, with COX products being higher and LOX products being lower. ASA reduced COX products, cyst growth and kidney water content, while NDGA reduced LOX products without altering disease progression or kidney function. Hence, a human equivalent ASA dose equal to less than one regular strength aspirin per day slowed disease progression, while further reduction of LOX products did not worsen disease progression.

UR - http://www.scopus.com/inward/record.url?scp=84912016673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84912016673&partnerID=8YFLogxK

U2 - 10.1016/j.prostaglandins.2014.10.005

DO - 10.1016/j.prostaglandins.2014.10.005

M3 - Article

C2 - 25447343

AN - SCOPUS:84912016673

VL - 116-117

SP - 19

EP - 25

JO - Prostaglandins and Other Lipid Mediators

JF - Prostaglandins and Other Lipid Mediators

SN - 1098-8823

ER -